Telix Appoints David Gill as Chair
Melbourne (Australia) and Indianapolis, IN (United States) | September 1, 2026
• David Gill appointed Chair of the Telix Board, effective immediately.
• Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.
• Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair.
Telix today announces that David Gill has been appointed Chair of the Board, effective immediately.
Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company’s Board expansion and succession planning[1], with the intention that he would be appointed Chair in due course. He succeeds Dr. Mark Nelson, who has served as interim Chair and will remain on the Board as a Non-Executive Director.
Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceutical development, manufacturing and supply chain) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc., and huMannity Medtec.
Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turnaround strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.
Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said, “I am delighted to welcome David as Chair of Telix. His global life sciences leadership – including extensive experience in radiopharmaceuticals – along with financial and capital markets expertise, will be invaluable as Telix continues to scale. I would also like to thank Mark for his leadership as interim Chair and look forward to his continued contribution as a Non-Executive Director.”
[1] Telix ASX disclosure April 2, 2026.